Analysts: Teva’s Outlook Gradually Improving and 3 Other Research Notes to Check Out

Teva (NYSE:TEVA): After meeting with Teva line managers, Bernstein thinks the company will be able to reduce its costs by close to the promised $1.75 billion. The firm believes the company’s respiratory drugs look solid, and it keeps a $47 price target and an Outperform rating on the shares.

TEVA-20131007